Obstructive sleep apnea is a chronic disorder that is characterized by the stop or pause breathing or shallow breathing during sleep. People with obstructive sleep apnea pause their breathing more than normal and start breathing again with loud or choking sound. Based on the frequency of pause in breathing, the amount of sleepiness, and level of oxygen in the blood, the disease can be categorized into mild, moderate and severe degrees. If left untreated, obstructive sleep apnea can lead to daytime sleepiness and also increase the risk of occurrence of metabolic disease. The University of Alabama at Birmingham is in the process of developing ketamine as a N-methyl-D-aspartate receptor blocker for the treatment of obstructive sleep apnea. National Heart, Lung, and Blood Institute is in the process of developing fluticasone as a glucocorticoid receptor agonist for the treatment of obstructive sleep apnea. Some of the companies/universities having the pipeline of obstructive sleep apnea include University of British Columbia, Nanjing Medical University, Jazz Pharmaceuticals, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.